Atyr Pharma Beats Q4 Loss Estimates, Schedules FDA Meeting on Phase 3 Efzofitimod
Atyr Pharma reported a Q4 loss of $14 million (-$0.14 per share) beating estimates of a -$0.18 loss, and full-year outflow widened to $74.1 million on $190,000 revenue, while ending 2025 with $80.9 million in cash. The company plans an FDA meeting in mid-April to discuss Phase 3 efzofitimod results.
1. Fourth Quarter and Full Year Financial Results
Atyr Pharma reported a fourth quarter net loss of $14 million, or $0.14 per share, compared to analysts’ expected loss of $0.18 per share. For full-year 2025, net outflow widened to $74.1 million, flat revenue of $190,000 was recorded, and shares last traded near $0.90.
2. Clinical Pipeline and Upcoming FDA Meeting
The company ended 2025 with $80.9 million in cash, cash equivalents and investments. A Type C meeting with the FDA is scheduled for mid-April to review Phase 3 EFZO-FIT™ study data in pulmonary sarcoidosis, which missed its primary steroid-reduction endpoint but showed statistical benefit on quality-of-life and lung function measures. Enrollment in the Phase 2 EFZO-CONNECT™ systemic sclerosis ILD study remains on track for completion in H1 2026, and preclinical data on ATYR0101 subcutaneous delivery continue to support its anti-fibrotic potential.